Unlocking the Dark Metaproteome: De Novo Protein Sequencing Reveals Hidden Microbial Proteins and Druggable Targets

▤ Summary

Rapid Novor describes a Nature Communications study that uses de novo protein sequencing and PASEF-enabled mass spectrometry to expose proteins in the dark metaproteome. The workflow combines uMetaP and novoMP to improve sensitivity, expand peptide identification, and strengthen taxonomic and functional insights in complex microbiome samples. The company says its software helped uncover proteins that conventional database searches miss. The study also frames these findings as a step toward identifying druggable targets for Crohn's disease and other intestinal inflammatory diseases.

▦ Linked Companies

Rapid Novor

$1M to $5M